AMD has pulled back from its recent highs, and the options market is registering a subtle but measurable shift back toward caution after last week's burst of bullish repositioning.
The stock closed Tuesday at $607.57, down 2.6% on the week and off from the $630 print that anchored the previous note. That retreat matters in context: AMD had just broken above the mean analyst price target of $618, a milestone that prompted B of A's Vivek Arya to lift his target to $720. The stock is now trading back below that consensus mean. It is still up 30% over the past month, so the longer-term move is intact, but the short-term momentum has stalled.
Options positioning has retraced some of the bullish rotation documented a week ago. The put/call ratio has climbed back to 1.11, essentially in line with its 20-day average of 1.12 and a z-score of just -0.36. Two weeks ago the PCR had dropped to 1.07 with a z-score of -2.23, the most call-skewed reading of the past month. That extreme has unwound. Traders are not yet buying downside protection at an unusual rate, but the aggressive call-side tilt has clearly faded. Short interest adds relatively little colour here: at 2.4% of free float, down nearly 10% on the week, it remains low and falling. Borrow availability is effectively unlimited, and cost to borrow, while up 32% on the week to 0.37%, is still trivially cheap in absolute terms. Shorts are not a meaningful force in this stock right now.
The Street remains broadly constructive, though the week's analyst activity was largely reiterative. StoneX and Rosenblatt both maintained Buy ratings with targets of $685 and $700 respectively, both above current price. The bullish case rests on AMD's most recent quarter, where revenue hit $11.54 billion (up 50% year on year), data centre revenue reached a record $6.72 billion (up 107%), and management guided for data-centre revenue to grow well over 100% in 2027. The bear case centres on the planned $8.2 billion all-stock acquisition of World Labs, which adds dilution and integration risk without enough disclosure to quantify the earnings impact, plus competitive pressure from Nvidia in GPUs and a softening PC market in the second half of 2026. The PE multiple has expanded roughly 7.8 points over the past 30 days to just under 45x, and EV/EBITDA has come in about 3 points over the same period to 39x, a valuation profile that leaves little room for execution missteps. EPS momentum scores remain strong at 81 and 80 on the 30 and 90-day windows respectively, which gives bulls a fundamental anchor even at a stretched multiple.
Retail attention is running above its own recent history: the ORTEX alt data layer shows Wikipedia-derived attention with a z-score of 1.64 against AMD's own prior 90 days as of September 22. That is not a revenue indicator, but it does suggest AMD remains unusually prominent in retail consciousness relative to its own baseline, consistent with the stock's extraordinary year-to-date gain of more than 183%.
On the institutional side, JP Morgan Asset Management added the most shares in the latest reported period, adding roughly 12.8 million shares to reach 1.8% of outstanding. FMR (Fidelity) added 10.5 million shares to reach 1.3%. BlackRock, the largest holder at 9.2%, added 4.7 million. The direction of large institutional flow is clearly positive, which has been a consistent feature of the ownership picture through the entire 2026 rally.
Q3 earnings land on November 3, 34 days away. After the August print, AMD fell 0.5% the next day and another 2.1% over the following week, a muted reaction that suggests the market had positioned reasonably well. The more interesting question heading into November is whether the data-centre revenue ramp and any updated commentary on the World Labs deal can sustain the premium multiple, or whether the stock's retreat back below the analyst consensus mean marks the beginning of a more extended consolidation.
See the live data behind this article on ORTEX.
Open AMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
